ContributorsPublishersAdvertisers

Pembrolizumab Yields Significantly Improved Disease-Free Survival in Non–Small Cell Lung Cancer

cancernetwork.com
 2022-01-10

Cover picture for the articlePatients with stage IB to IIIA non–small cell lung cancer saw an improvement in disease-free survival when treated with pembrolizumab compared with the placebo regardless of PD-L1 expression. Patients with stage IB to IIIA non–small cell lung cancer (NSCLC) who were treated with pembrolizumab (Keytruda) following surgical resection...

www.cancernetwork.com

Comments / 0

Comments / 0